Introduction {#s1}
============

Heart failure (HF) is not a single organ disease but rather a multifaceted syndrome, which can result in psychological, musculoskeletal, hematological, pulmonary, endocrine, endothelial, renal and hepatic impairment \[[@R01]\]. The muscle hypothesis of HF proposed that "exercise performance in HF patients is predominantly limited by skeletal muscle and less by the performance of cardiac muscle" \[[@R02]\]. Handgrip strength (HGS) is the maximum force that can be generated by the hand and forearm musculature during a single isometric contraction and as such is a measure of skeletal muscle performance. HGS correlates well with overall body strength, is used as a marker of exercise capacity, general health and nutritional status and deteriorates with aging and chronic disease. In HF, HGS can be used to stratify patients according to functional class, peak VO~2~ and is an independent predictor of survival \[[@R03]\]. Previous clinical trials have shown pharmacotherapies commonly used in HF, such as angiotensin converting enzyme (ACE) inhibitors, to preserve lean body weight but not affect skeletal muscle function \[[@R08], [@R09]\].

Cardiac resynchronization therapy (CRT) is a widely used treatment in HF; it improves the hearts pumping efficiency by restoring synchronous contraction of the atria and ventricles. Benefits include improved quality of life and exercise capacity and reduced hospitalization and mortality \[[@R10]\]. Despite meeting strict implantation criteria, only two-thirds of patients respond to this complex device therapy and it still remains unclear as to why this is the case \[[@R11]\].

To date, no trial has investigated the role of CRT influencing skeletal muscle performance, such as measuring HGS, presenting a means of differentiating between responders and non-responders, at baseline and during follow-up. If HGS, a simple, inexpensive and reliable test could be used to differentiate likely responders from non-responders at baseline pre-CRT implantation, then this would be invaluable to clinicians, patient groups and researchers alike. Furthermore, any differences in HGS as a result of CRT identified during follow-up would further refine current understanding of response to CRT and possible reasons underlying non-response.

Methods {#s2}
=======

Ethics approval and consent to participate {#s2a}
------------------------------------------

All patients gave fully informed written consent to take part in the project. The project was conducted in compliance with the principles of the Declaration of Helsinki (October 2008), the principles of Good Clinical Practice (GCP) and all of the applicable regulatory requirements. The project was approved by the National Research Ethics Service (NRES) number 10/H0802/71.

Recruitment {#s2b}
-----------

Patients were screened for eligibility by a physician and a dedicated clinical research fellow. Nineteen patients who received CRT based on current clinical criteria used at Sheffield Teaching Hospitals (STH) NHS Trust were recruited for this study, i.e., patients with an ejection fraction \< 35%, a QRSd \> 120 ms, NYHA functional class II-IV and optimal medical therapy. No patients had a history of wrist or hand arthritis and patients were examined specifically prior to starting the study.

Study design {#s2c}
------------

The study was a prospective cohort study using an opportunity sample. All patients recruited to the study had their HGS assessed at baseline, 6 and at 12 months (± 2 weeks) post-CRT implantation. At the same time points, they underwent echocardiography and cardiopulmonary exercise testing (CPET) to measure their peak VO~2~ and completed the Minnesota Living With Heart Failure Questionnaire (MLWHFQ). At 6 weeks after CRT implantation, all patients were referred for routine echocardiography-guided CRT optimization, using the iterative method to optimize atrio-ventricular delay and the aortic velocity time integral method for the inter-ventricular delay.

Assessment of grip strength {#s2d}
---------------------------

HGS was measured at baseline, 6 and 12 months using a single protocol; patients were asked to perform three maximal trials with each hand using a Jamar analogue dynamometer on the morning of testing. The patients were all positioned according to the American Society of Hand Therapists (ASHT) guidance \[[@R11]\]. Standardized verbal instructions and encouragement were used as recommended by Mathiowetz et al (1984) \[[@R12]\]. The investigator carrying out HGS measurement was blinded to markers of response to CRT. The analogue Jamar dynamometer used to measure HGS had excellent test-retest (r = 0.88 - 0.93) and inter-rater (r = 0.99) reliability \[[@R12]\]. Measurement of HGS was known to be sensitive to a range of factors such as patient encouragement, time of day, posture, the position of the upper limb joints (shoulder, elbow, and wrist) and even the position of the dynamometer handle itself, hence it was essential to use a standardized approach \[[@R13]\]. There was a learning effect with using the dynamometer and in an attempt to negate this, the best of three attempts for both right and left hands was used.

Assessment of response to CRT {#s2e}
-----------------------------

A positive response to CRT was defined *a priori* by the authors, as a significant improvement in all of four different outcome measures, a \> 1 mL/kg/min increase in peak VO~2~, a \> 15% reduction in left ventricular end-diastolic volume (LVEDV), a \> 10% increase in 6-min walk distance (6MWD) and a \> 10 point reduction in symptoms as measured by the MLWHFQ quality of life (QoL) questionnaire.

CPET consisted of a ramp protocol on a static bicycle ergometer to measure peak VO~2~ supervised by a senior pulmonary physiologist. Peak VO~2~ was the highest measure of VO~2~ attained, but not necessarily that, which would be ultimately attainable and had been shown to improve significantly in responders to CRT.

LVEDV was calculated using the modified Simpson's rule of stack discs using apical two- and four-chamber views by two-dimensional echocardiography General Electric (GE Healthcare, Princeton, NJ) Vivid 7 ultrasound machine, assessed by senior echocardiographers.

The 6-min walk test (6MWT) measured the distance walked at a normal pace on a flat, hard, even surface in 6 min, the 6MWD.

The MLWHFQ was a validated and well-tested questionnaire assessing the impact of HF on QoL, and specifically it asked questions on domains relating to both psychological and physiological factors, including questions on the side-effects of treatments, hospital admissions, symptoms, mood, sex-life and appetite. The investigators administered the questionnaire.

Statistical analysis {#s2f}
--------------------

Statistical analysis was performed using SPSS software (version 21.0, SPSS Inc., Chicago, IL, USA). Assessment of data for normality was carried out using both visual assessment of the data and Shapiro-Wilks test. Categorical data were analyzed using a two-tailed Fisher's exact test. Parametric data are given in terms of the mean ± SD. Comparison of data between groups at baseline was performed using an unpaired two-tailed Student's *t*-test. Comparison of data within groups during follow was performed using one-way ANOVA with repeated measures. Correlations were analyzed with the Pearson's correlation coefficient. P values of \< 0.05 were considered significant.

Results {#s3}
=======

Nineteen patients were included in the study. The baseline patient characteristics are shown in [Table 1](#T1){ref-type="table"}. As can be seen, all patients had similarly impaired LV function at baseline and a prolonged QRS duration. Furthermore, there were no statistically significant differences between the baseline measures of response, such as LVEDV, peak VO~2~, 6MWD or MLWHFQ ([Table 1](#T1){ref-type="table"}).

###### Baseline Characteristics of Responders and Non-Responders Pre-CRT Implantation

                                Responders (N = 14)   Non-responders (N = 5)   P value           
  ----------------------------- --------------------- ------------------------ --------- ------- --------
  Demographics                                                                                   
    Age (years)                 68.4                  9.8                      71.8      4.2     0.53
    Gender (male)               13                    93%                      5         100%    0.99\*
    Handedness (right)          14                    100%                     5         100%    0.99\*
    Body mass index (kg/m^2^)   29.6                  3.98                     26.5      4.41    0.18
    Ischemic heart disease      8                     57%                      3         60%     0.99\*
    Hypercholesterolemia        10                    72%                      4         80%     0.99\*
    Hypertension                7                     50%                      2         40%     0.99\*
    Chronic kidney disease      4                     29%                      4         80%     0.11\*
    Diabetes                    5                     36%                      1         20%     0.99\*
  ECG/echocardiography                                                                           
    QRSd (ms)                   163.0                 22.8                     155.5     20.9    0.55
    EF (%)                      25.6                  8.0                      25.8      8.5     0.44
  Medications                                                                                    
    ACEI/ARB                    13                    93%                      5         100%    0.99\*
    Beta-blocker                12                    86%                      5         100%    0.99\*
    Loop diuretic               14                    100%                     5         100%    0.99\*
    Spironolactone              9                     64%                      4         80%     0.99\*
  Markers of response                                                                            
    6MWD (m)                    374.0                 112.8                    337.0     144.7   0.23
    LVEDV (mL)                  201.5                 72.5                     159.0     80.8    0.37
    MLWHFQ                      44.4                  22.9                     52.8      22.7    0.33
    Peak VO~2~ (mL/kg/min)      12.5                  1.6                      13.9      2.7     0.25
  Hand grip strength (kgf)                                                                       
    Left                        34.4                  11.4                     33.0      5.3     0.42
    Right                       35.7                  12.5                     31.2      12.2    0.25

Mean or number given in right hand column and % or SD given in left hand column. \^Comparisons between groups analyzed using two-tailed unpaired Student's *t*-test unless categorical data (\*) compared using Fisher's exact test. ACE: angiotensin converting enzyme inhibitor; ARB: angiotensin receptor blocker; CRT: cardiac resynchronization therapy; ECG: electrocardiography; EF: ejection fraction; LVEDV: left ventricular end-diastolic volume; QRSd: QRS duration.

Response to CRT {#s3a}
---------------

A positive response to CRT in the four criteria was observed in 14 of the 19 patients after 12 months of CRT ([Table 2](#T2){ref-type="table"}).

###### Markers of Response at 0 (Baseline), 6 and 12 Months Follow-Up in Responders and Non-Responders

  Markers of response        Baseline, mean ± SD   6 months, mean ± SD   12 months, mean ± SD   One-way ANOVA with repeated measures P value   
  -------------------------- --------------------- --------------------- ---------------------- ---------------------------------------------- ---------
  Responders (N = 14)                                                                                                                          
    6MWD (m)                 374.0 ± 112.8         391.0 ± 108.1         418.1 ± 105.3          \< 0.05                                        \< 0.05
    LVEDV (mL)               175.1 ± 67.2          157.0 ± 77.3          121.3 ± 72.0           \< 0.05                                        \< 0.05
    MLWHFQ/105               44.4 ± 22.9           24.4 ± 19.1           24.1 ± 21.3            \< 0.05                                        \< 0.05
    Peak VO~2~ (mL/kg/min)   12.5 ± 1.6            14.1 ± 2.7            14.7 ± 1.5             \< 0.05                                        \< 0.01
  Non-responders (N = 5)                                                                                                                       
    6MWD (m)                 337.0 ± 144.7         279.2 ± 155.5         279.6 ± 113.8          0.34                                           
    LVEDV (mL)               159.0 ± 80.8          172.4 ± 126.2         145.6 ± 88.8           0.63                                           
    MLWHFQ/105               52.8 ± 22.7           37.0 ± 20.6           36.4 ± 26.7            0.31                                           
    Peak VO~2~ (mL/kg/min)   13.9 ± 2.7            11.5 ± 4.1            12.8 ± 3.9             0.21                                           

LVEDV: left ventricular end-diastolic volume; MLWHFQ: Minnesota Living With Heart Failure Questionnaire; 6MWD: 6-minute walk distance.

A one-way ANOVA with repeated measures and Greenhouse-Geisser correction determined that peak VO~2~ (F(1.27, 13.9) = 9.26, P \< 0.01), LVEDV (F(1.73, 17.3) = 6.73, P \< 0.01), MLWHFQ (F(1.97, 21.76) = 7.40, P \< 0.01) and 6MWD (F(1.93, 21.03) = 22.67, P \< 0.01) in responders was statistically different between time points during follow-up. *Post hoc* analysis using the Bonferroni correction demonstrated responders had statistically significant differences between baseline and 6 months and baseline and 12 months in 6MWD ([Fig. 1A](#F1){ref-type="fig"}), peak VO~2~ ([Fig. 1B](#F1){ref-type="fig"}), MLWHFQ score ([Fig. 1C](#F1){ref-type="fig"}) and LVEDV ([Fig. 1D](#F1){ref-type="fig"}).

![The markers of response to cardiac resynchronization therapy, at time zero (baseline) before implantation, 6 and 12 months following CRT implantation in responders (white): (A) 6-minute walk distance (6MWD); (B) peak VO~2~; (C) Minnesota Living With Heart Failure Questionnaire (MLWHFQ) score; (D) left ventricular end-diastolic volume (LVEDV). Differences in data from baseline to 6 and 12 months compared using one-way ANOVA with repeated measures.](cr-07-095-g001){#F1}

Non-responders failed to demonstrate a significant difference in any of these four markers between time points according to a one-way ANOVA with repeated measures ([Table 2](#T2){ref-type="table"} and [Fig. 2A-D](#F2){ref-type="fig"}).

![The markers of response to cardiac resynchronization therapy, at time zero (baseline) before implantation, 6 and 12 months following CRT implantation in non-responders (black). (A) 6-minute walk distance (6MWD); (B) peak VO~2~; (C) Minnesota Living With Heart Failure Questionnaire (MLWHFQ) score; (D) left ventricular end-diastolic volume (LVEDV). Data during follow-up compared using one-way ANOVA with repeated measures, with no significant difference.](cr-07-095-g002){#F2}

There was no significant difference in the workload (Watts) measured at peak VO~2~ at baseline between the responders and non-responders (91.2 ± 24.9 W and 93.2 ± 18.7 W, P = 0.29), using an unpaired Student's *t*-test.

A one-way ANOVA with repeated measures that did not violate Mauchly's test of sphericity determined that workload in responders was statistically different between time points in (F(2, 22) = 4.45, P \< 0.05) but not non-responders (F(2, 6) = 0.91, P = 0.45). *Post hoc* analysis using pairwise comparisons in responders only revealed that workload approached statistical significance between baseline and 6 months and baseline and 12 months ([Fig. 3](#F3){ref-type="fig"}), but not 6 and 12 months (data not shown).

![The peak workload (watts) measured during cardiopulmonary exercise testing in (A) responders (white) and (B) non-responders (black) at time zero (baseline) before implantation and then 6 and 12 months following CRT, compared using one-way ANOVA with repeated measures.](cr-07-095-g003){#F3}

Hand grip strength {#s3b}
------------------

There were no statistically significant differences between the HGS of responders and non-responders at baseline ([Table 1](#T1){ref-type="table"}). There were also no statistically significant differences in HGS in responders and non-responders between the left and right hands (data not shown).

A one-way ANOVA with repeated measures and Greenhouse-Geisser correction determined mean HGS in responders was statistically different between time points in the left (F(1.77, 17.71) = 21.03, P \< 0.001) and the right (F(1.36, 13.58) = 16.03, P \< 0.01) hand. *Post hoc* tests using the Bonferroni correction revealed that HGS increased statistically significantly between baseline and 6 months and baseline and 12 months, but not 6 and 12 months (data not shown), in both hands ([Table 3](#T3){ref-type="table"} and [Fig. 4A and B](#F4){ref-type="fig"}).

###### Handgrip Strength at 0 (Baseline), 6 and 12 Months Follow-Up in Responders and Non-Responders

  Handgrip strength        Baseline, mean ± SD   6 months, mean ± SD   12 months, mean ± SD   One way ANOVA with repeated measures P value   
  ------------------------ --------------------- --------------------- ---------------------- ---------------------------------------------- ----------
  Responders (N = 14)                                                                                                                        
    Left (kgf)             34.4 ± 11.4           39.7 ± 10.8           40.3 ± 11.3            \< 0.01                                        \< 0.001
    Right (kgf)            35.7 ± 12.5           39.8 ± 11.5           42.2 ± 11.2            \< 0.01                                        \< 0.001
  Non-responders (N = 5)                                                                                                                     
    Left (kgf)             33.0 ± 5.3            27.6 ± 8.9            25.0 ± 11.7            0.30                                           
    Right (kgf)            31.2 ± 12.2           30.8 ± 9.9            29.8 ± 8.1             0.66                                           

kgf: kilograms of force; SD: standard deviation.

![Mean handgrip strength in the left (A) and right hand (B) at zero (baseline), 6 and 12 months following cardiac resynchronization therapy (responders in solid gray line and non-responders in solid black line) with standard error bars.](cr-07-095-g004){#F4}

A one-way ANOVA with repeated measures and Greenhouse-Geisser correction determined that there were no statistical differences between time points in the left (F(1.05, 4.22) = 1.29, P= 0.30) or right (F(1.12, 4.49) = 0.24, P = 0.66) hand ([Table 3](#T3){ref-type="table"} and [Fig. 4A and B](#F4){ref-type="fig"}) of non-responders.

Hand grip strength and CRT {#s3c}
--------------------------

Pearson's correlation coefficient compared mean HGS with 6MWD during follow-up over the 12 months ([Fig. 5A and B](#F5){ref-type="fig"}, respectively), which proved significant in both the left (r = 0.5160, n = 57, P \< 0.001) and right (r = 0.6821, n = 57, P \< 0.001) hands.

![Correlation between handgrip strength (right and left) and 6-minute walk distance (6MWD) in the left (A) and right (B) hands both responders and non-responders, compared using Pearson's correlation coefficient.](cr-07-095-g005){#F5}

Discussion {#s4}
==========

This study demonstrates, for the first time, a difference in HGS between responders and non-responders to CRT. At baseline, there is no significant difference in skeletal muscle function as measured by HGS. During follow-up however, there is a significant improvement in HGS, and whilst non-significant, there is also a decline in HGS in the non-responders. This is despite no other significant difference in physical performance between the two groups at baseline. The improvement in HGS of 17-20% is similar to gains considered significant in other metrics of response such as LVEDV, peak VO~2~ or MLWHFQ. These results suggest that, by improving cardiac function in responders, CRT better enables patients to perform activities of daily living and so regain strength of the skeletal muscles. Furthermore, the positive correlation with 6MWD suggests that HGS is a real-world assessment of fitness; indeed at 12 months follow-up, every 1.5 kgf increase in HGS correlated with a 10 m increase in 6WMD.

It is unlikely that CRT has a direct effect on skeletal muscle other than a possible improvement of nutritive flow to the tissue, as a result of increased cardiac output \[[@R14]\]. To investigate possible mechanisms, skeletal muscle biopsy could be utilized to see what changes occur in skeletal muscle fiber distribution, metabolism, mitochondria and respiration, known to deteriorate in HF, improved as a consequence of CRT \[[@R15]\].

The assumption is made that gains in HGS reflect increased muscle performance throughout the body, but it would be interesting to measure this in terms of function of other major muscle groups such as the quadriceps and knee extension strength \[[@R07]\]. Whilst there were no significant differences at baseline in any CPET measures, there were increases in peak VO~2~ and peak workload but not anaerobic threshold (data not shown). Whilst the changes in workload approached significance, unlike peak VO~2~, this suggests that response to CRT leads to specific gains in isometric strength in the upper limbs measured by HGS, and this may also translate into more generalized improvements in skeletal muscle function, demonstrated by increase in workload in the lower limbs.

Sarcopenia is defined as the "age-associated loss of skeletal muscle mass and function" which is common in HF and independently associated with reduced exercise performance even when age, sex, functional class and co-morbidities are controlled for \[[@R21], [@R22]\]. However, in the absence of a measure of lean mass, this study investigated only differences in HGS, also known as dynapenia \[[@R23]\]. Whilst gains in HGS may be due to increased motor recruitment, myocyte hypertrophy may also be involved with CRT leading to a reversal of sarcopenia; measurement of lean mass by bioelectric impedance, dual energy X-ray absorptiometry or appendicular muscle volume by MRI would be needed to corroborate these findings and thus assess muscle mass and function, not just dynapenia. Clearly, measuring gross weight alone is fraught with error, as the HF condition leads to fluid retention and significant fluctuations in weight, but not muscle mass.

A possible confounder is serum albumin, an indicator of nutrition and associated with skeletal muscle performance \[[@R24]\]. Differences between the groups could reflect a more nutritionally replete/deplete cohort (as with HGS). However, serum albumin concentrations (mean and SD) were within normal limits (reference range 35 - 50 g/L) for all patients and no statistically significant difference was found during follow-up in either group (data not shown). Serum albumin is influenced by other co-morbidities such as liver and renal disease, all of which remained stable throughout the 12-month period of assessment. Furthermore, future research would be needed to ensure patients are consuming consistently 25 - 30 g high quality protein at breakfast, lunch and dinner, to provide sufficient protein to effectively stimulate muscle protein anabolism and adequately control for this extraneous variable \[[@R27]\].

Importantly, there were no statistically significant differences at baseline between the two groups. Although there were some non-significant differences, this is likely to be due to the small sample size. This cohort was a small but homogenous sample, but there were no ethnic minorities and only one woman and so it is difficult to translate the results to such populations. Whilst any improvement in HGS following a positive response to CRT implantation is correlation, not causation, there were no other significant clinical interventions during the 12 months follow-up.

Defining response to CRT is problematic and subjective, for this reason the authors decided that any responder must demonstrate improvement in four completely different markers at certain thresholds, widely used in the literature, but not collectively \[[@R11], [@R28]\]. This was to ensure, as much as possible, that any response was true and not due to random variation, particularly in such a small patient population. Indeed, there was an improvement, albeit non-significant, in the MLWHFQ score in non-responders, but this is likely to be due to chance or placebo effect, especially as this was associated with no other response.

Taking into account both age and disease, this patient cohort has similar values of HGS to those reported in other CHF studies \[[@R05], [@R07]\]. The only intervention study examining HGS and HF demonstrated an increase in HGS of 2 kgf following a 3-month exercise programme \[[@R06]\]. The present CRT study demonstrates that similar gains at 12 months are found in CRT in patients who respond, on average 18% increase per hand. CRT allows patients to increase their own activity voluntarily, rather than as part of a specific exercise programme. It would be interesting to see if, as Belardinelli et al (2006) found with flow mediated dilatation (FMD) and endothelial dysfunction, further gains in HGS could be achieved by the adoption of an exercise programme and what, if any, effect this might have on other markers of response \[[@R31]\]. To date, there are no studies examining HGS in HF patients before and after routine cardiac rehabilitation. A recent study however demonstrated that exercise training in HF patients led to increases in muscle force and reductions in the levels of MuRF-1, a component of the ubiquitin-proteasome system involved in muscle proteolysis, which is increased in the skeletal muscle of patients with HF \[[@R32]\]. It would be interesting to see what impact positive response CRT also had on such a biomarker.

There were no clinical events during 12 months follow-up, such as hospitalizations or deaths in either group, but in larger trials with longer follow-up, it would be interesting to see if such improvements in HGS were correlated with reductions in adverse events such as morbidity and mortality.

Conclusions {#s4a}
-----------

This study demonstrates for the first time that there are significant improvements in the skeletal muscle performance of CRT responders, which correlates with 6MWD. This supports the notion that HGS is a simple, quick and inexpensive method of identifying responders to CRT. However, there are no significant differences in HGS between responders and non-responders to CRT at baseline, and so based on this study, it cannot be used to identify responders.

This improvement in HGS may reflect the fact that HF is not purely a single organ disease and so such measures before and after initiating HF therapies should be considered to corroborate improvement in symptoms and ensure this is not simply due to response bias, placebo or conformity. If larger studies demonstrated differences in HGS at baseline, the prospect of using a single simple test such as HGS to predict response to CRT remains a tantalizing possibility.

This was a small study in a homogenous population and so the findings will need replication in larger, diverse cohorts with such measurements at baseline and follow-up. Finally, further research is needed to investigate the mechanism between CRT and improved HGS.
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